PD-L1 expression is routinely measured by immunohistochemistry (IHC) to predict the tumor response to PD-L1 inhibitors in particular tumor types, such as lung cancer, but the significance of this marker in BTCs is contradictory [4]. Here, CD274 is linked to neoplasm.